基于重复测量方差分析观察黄葵胶囊联合氯沙坦钾治疗糖尿病肾脏病Ⅲ期的临床疗效

doi:10.3969/j.issn.1006-5253.2022.05.003

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (4028 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的采用重复测量方差分析探讨黄葵胶囊联合氯沙坦钾治疗糖尿病肾脏病Ⅲ期的临床疗效。方法采用随机数字表法将糖尿病肾脏病Ⅲ期患者分为试验组(n=43)与对照组(n=43)。所有患者均接受相同的基础治疗，对照组患者给予氯沙坦钾治疗，试验组患者在对照组的基础上加用黄葵胶囊。于治疗前、治疗后4周、治疗后8周、治疗后12周分别测量2组患者的24 h尿微量白蛋白定量（24 h urinary protein，Upro）、尿肾损伤分子-1（urinary kidney injury molecule-1，UKim-1）以及尿β-2-微球蛋白（urinary β-2-microglobulin, Uβ-2-MG）水平；比较治疗前及治疗后12周2组患者中医临床证候积分差异。结果重复测量方差分析结果显示，2组患者的Upro、Uβ-2-MG的时间效应、组间效应和交互效应差异均具有统计学意义（P＜0.05），2组患者的UKim-1只有时间效应具有统计学意义（P＜0.05）。单因素重复测量方差分析结果表明试验组患者与对照组患者Upro以及Uβ-2-MG水平随治疗时间变化趋势不同。多变量方差分析结果显示：试验组治疗后4周、治疗后8周以及治疗后12周的Upro水平均低于对照组（P＜0.05）；试验组治疗后8周以及治疗后12周的Uβ-2-MG水平低于对照组（P＜0.05）。治疗12周后试验组中医临床证候积分低于对照组（P＜0.05）。结论黄葵胶囊联合氯沙坦钾治疗糖尿病肾脏病Ⅲ期疗效优于单纯使用氯沙坦钾治疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王文文
	林永强
	王超超
	姜益

关键词 ：重复测量方差分析, 黄葵胶囊, 氯沙坦钾, 糖尿病肾脏病

Abstract：Objective To explore the clinical effect of Huangkui capsule combined with losartan potassium in the treatment of diabetic kidney disease stage Ⅲ by using repeated measurement analysis of variance (ANOVA).Methods Patients with stage Ⅲ diabetic kidney disease were divided into the experimental group (n=43) and the control group (n=43) by random number table method. All patients received the same basic treatment, the control group was given losartan potassium treatment, and the experimental group was treated with Huangkui capsule besides the treatment in the control group. The 24-hour urinary protein(Upro), urinary kidney injury molecule-1 (Ukim-1), and Urinary β-2-microglobulin (Uβ-2-MG) were measured before the treatment, 4 weeks after the treatment, 8 weeks after the treatment, and 12 weeks after the treatment in both groups, and the difference of TCM clinical syndrome scores between the two groups was evaluated before the treatment and 12 weeks after the treatment.Results The results of repeated measurement ANOVA showed that the time effect, inter group effect and interaction effect of Upro and Uβ-2-MG in the two groups were statistically significant (P<0.05), and only the time effect of Ukim-1 in the two groups was statistically significant (P<0.05). The results of one-way repeated measurement ANOVA showed that the levels of Upro and Uβ-2-MG in the experimental group and the control group had different trends with the treatment time. The results of multivariate analysis of variance showed that the level of Upro in the experimental group was lower than that in the control group at 4 weeks, 8 weeks and 12 weeks after the treatment (P<0.05). The level of Uβ-2-MG in the experimental group at 8 weeks and 12 weeks after the treatment was lower than that in the control group (P<0.05). After 12 weeks of the treatment, the TCM clinical syndrome score in the experimental group was significantly lower than that in the control group (P<0.05).Conclusion Huangkui capsule combined with losartan potassium is superior to losartan potassium alone in the treatment of stage Ⅲ diabetic kidney disease.

Key words： repeated measurement analysis of variance Huangkui capsule losartan potassium diabetic kidney disease

收稿日期: 2022-03-29

PACS:

基金资助: 温州市基础性医疗卫生科技项目（Y20190734）

通讯作者: 王文文，Email：wangwenwen888@126.com

引用本文:

王文文，林永强，王超超，姜益. 基于重复测量方差分析观察黄葵胶囊联合氯沙坦钾治疗糖尿病肾脏病Ⅲ期的临床疗效[J]. 中国医院统计, 2022, 29(5): 331-336.
Wang Wenwen, Lin Yongqiang, Wang Chaochao, Jiang Yi. Clinical efficacy of Huangkui capsule combined with losartan potassium in the treatment of diabetic kidney disease stage Ⅲ by using repeated measurement analysis of variance. journal1, 2022, 29(5): 331-336.

链接本文:

http://manu58.magtech.com.cn/Jwk_zgyytj/CN/10.3969/j.issn.1006-5253.2022.05.003 或 http://manu58.magtech.com.cn/Jwk_zgyytj/CN/Y2022/V29/I5/331

［1］YAMAZAKI T, MIMURA I, TANAKA T, et al. Treatment of diabetic kidney disease: Current and future［J］. Diabetes Metab J, 2021, 45(1):11-26. DOI:10.4093/dmj.2020.0217.

［2］SAMSU N. Diabetic nephropathy: Challenges in pathogenesis, diagnosis, and treatment［J］. Biomed Res Int, 2021:1497449. DOI:10.1155/2021/1497449.

［3］XU L N, ZHAO B, WANG H T, et al. Tripterygium wilfordii hook F treatment for stage IV diabetic nephropathy: Protocol for a prospective, randomized controlled trial［J］. Biomed Res Int, 2020:9181037. DOI:10.1155/2020/9181037.

［4］董必成．尿毒清颗粒联合ACEI或ARB治疗Ⅲ期糖尿病肾病的Meta分析［D］．南昌：江西中医药大学，2021．

［5］ZUO C, XU G S. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta-analysis［J］. Int J Clin Pract, 2019, 16: e13413. DOI:10.1111/ijcp.13413.

［6］徐琳，李德，叶新华．盐酸贝那普利联合黄葵胶囊治疗糖尿病肾病的临床疗效及安全性观察［J］．中国中西医结合肾病杂志，2018，19(1)：72-73．DOI:10.3969/j.issn.1009-587X.2018.01.027.

［7］顾晶. 缬沙坦联合黄葵胶囊治疗高血压合并糖尿病肾病的疗效［J］. 中国老年学杂志, 2015,35(23):6747-6749.DOI: 10.3969/j.issn.1005-9202.2015.23.044.

［8］刘红，孙伟，顾刘宝，等．黄葵胶囊联合ACEI或ARB类药物治疗糖尿病肾病的Meta分析［J］．中华中医药杂志，2015，30(5)：1712-1718．

［9］冯国双．重复测量方差分析及SPSS实现［J］．中华全科医师杂志，2017，16(9)：740-742．DOI:10.3760/cma.j.issn.1671-7368.2017.09.024.

［10］郭迎暄，陈达，张双喆，等．基于C#与R语言的重复测量设计资料方差分析的自动化实现［J］．中国医院统计，2021，28(4)：365-371．DOI:10.3969/j.issn.1006-5253.2021.04.017.

［11］中华医学会糖尿病学分会微血管并发症学组．中国糖尿病肾脏疾病防治临床指南［J］．中华糖尿病杂志，2019，11(1)：15-28．DOI:10.3760/cma.j.issn.1674-5809.2019.01.004.

［12］MOGENSEN C E, KEANE W F, BENNETT P H, et al. Prevention of diabetic renal disease with special reference to microalbuminuria［J］. Lancet, 1995, 346(8982):1080-1084. DOI:10.1016/s0140-6736(95)91747-0.

［13］杨霓芝，刘旭生．糖尿病肾病诊断、辨证分型及疗效评定标准:试行方案［J］．上海中医药杂志，2007，41(7)：7-8．DOI:10.16305/j.1007-1334.2007.07.003.

［14］吴晓晶，胡旭珍，赵红波，等．清热化湿坚阴法治疗早期糖尿病肾脏疾病的临床疗效［J］．中国老年学杂志，2020，40(5)：932-936．DOI:10.3969/j.issn.1005-9202.2020.05.013.

［15］罗勇．益气活血、清热化湿法治疗糖尿病肾脏疾病(气虚湿瘀证)临床观察［D］．成都：成都中医药大学，2018．

［16］王晶．黄葵胶囊联合缬沙坦治疗糖尿病肾脏疾病的Meta分析［D］．沈阳：辽宁中医药大学，2019．

［17］ HAN W B, MA Q, LIU Y L, et al. Huangkui capsule alleviates renal tubular epithelial-mesenchymal transition in diabetic nephropathy via inhibiting NLRP3 inflammasome activation and TLR4/NF-κB signaling［J］. Phytomedicine, 2019, 57:203-214. DOI:10.1016/j.phymed.2018.12.021.

［18］ MISE K, HOSHINO J, UENO T, et al. Prognostic value of tubulointerstitial lesions, urinary N-acetyl-β-d-glucosaminidase, and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy［J］. Clin J Am Soc Nephrol, 2016, 11(4):593-601. DOI:10.2215/CJN.04980515.

［19］ KAPOULA G V, KONTOU P I, BAGOS P G. Diagnostic performance of biomarkers urinary KIM-1 and YKL-40 for early diabetic nephropathy, in patients with type 2 diabetes: A systematic review and meta-analysis［J］. Diagnostics (Basel), 2020, 10(11):E909. DOI:10.3390/diagnostics10110909.